BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32267633)

  • 1. [A woman with a skin lesion suspected for melanoma].
    Post NF; Huis In 't Veld E; Crijns MB
    Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32267633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
    Rogiers A; Thomas D; Vander Borght S; van den Oord JJ; Bechter O; Dewaele M; Rambow F; Marine JC; Wolter P
    Br J Dermatol; 2019 Feb; 180(2):421-422. PubMed ID: 30248172
    [No Abstract]   [Full Text] [Related]  

  • 3. Sweet syndrome in metastatic melanoma during treatment with dabrafenib and trametinib.
    Scarfì F; Melotti B; Veronesi G; Ravaioli GM; Baraldi C; Lambertini M; Patrizi A; Dika E
    Australas J Dermatol; 2019 Aug; 60(3):e242-e243. PubMed ID: 30724336
    [No Abstract]   [Full Text] [Related]  

  • 4. Pomalidomide, dabrafenib mesylate, and trametinib dimethyl sulfoxide.
    Hussar DA; Kaminski JL
    J Am Pharm Assoc (2003); 2013; 53(5):550-8. PubMed ID: 24030134
    [No Abstract]   [Full Text] [Related]  

  • 5. Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma.
    Zaloum A; Falet JR; Elkrief A; Chalk C
    Neurology; 2020 Feb; 94(7):322-323. PubMed ID: 31888971
    [No Abstract]   [Full Text] [Related]  

  • 6. Dabrafenib and trametinib combination therapy safely performed in a patient with metastatic melanoma after severe liver toxicity due to vemurafenib.
    Shimada S; Fukushima S; Niimori D; Miyashita A; Setoyama H; Sasaki Y; Ihn H
    J Dermatol; 2018 Jun; 45(6):e157-e158. PubMed ID: 29315749
    [No Abstract]   [Full Text] [Related]  

  • 7. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
    Dummer R; Hauschild A; Santinami M; Atkinson V; Mandalà M; Kirkwood JM; Chiarion Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Gasal E; Tan M; Long GV; Schadendorf D
    N Engl J Med; 2020 Sep; 383(12):1139-1148. PubMed ID: 32877599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
    Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
    J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
    [No Abstract]   [Full Text] [Related]  

  • 9. BRAF-mutated, acral verrucous melanoma successfully treated by dabrafenib plus trametinib combination therapy.
    Kiyohara T; Nagano N; Miyamoto M; Shijimaya T; Nakamaru S; Makimura K; Tanimura H
    Clin Exp Dermatol; 2019 Dec; 44(8):945-946. PubMed ID: 30950075
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
    Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
    N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma.
    Hennemann A; Puzenat E; Decreuse M; Vuillier F; Nardin C; Aubin F
    Melanoma Res; 2024 Jun; 34(3):280-282. PubMed ID: 38602773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tattoo-associated complications of metastatic melanoma treated with dabrafenib and trametinib.
    Laske J; Meier F; Bauer A; Beissert S; Garzarolli M
    Melanoma Res; 2018 Oct; 28(5):485-487. PubMed ID: 30148769
    [No Abstract]   [Full Text] [Related]  

  • 14. Dabrafenib (Tafinlar) and trametinib (Mekinist) metastatic melanoma.
    Med Lett Drugs Ther; 2013 Aug; 55(1422):62-3. PubMed ID: 23917385
    [No Abstract]   [Full Text] [Related]  

  • 15. Discrepancy in responses to dabrafenib plus trametinib combination therapy in intracranial and extracranial metastases in melanoma patients.
    Kobayashi T; Matsumoto S; Shimizu K; Miyake M; Maeda S; Hamaguchi Y; Matsushita T
    J Dermatol; 2021 Feb; 48(2):e82-e83. PubMed ID: 33161591
    [No Abstract]   [Full Text] [Related]  

  • 16. Repeated complete response with long-term control of BRAF-mutant melanoma by multiple rechallenges with dabrafenib plus trametinib.
    Sasaki K; Nakamura Y; Baba N; Teramoto Y; Yamamoto A
    Eur J Cancer; 2020 Nov; 139():37-40. PubMed ID: 32957012
    [No Abstract]   [Full Text] [Related]  

  • 17. A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.
    Marchand A; Tallet A; Collin C; Cormier B; Venel Y; Miquelestorena-Standley E; Machet L
    Br J Dermatol; 2018 Aug; 179(2):528-529. PubMed ID: 29494756
    [No Abstract]   [Full Text] [Related]  

  • 18. Evolution of melanocytic nevi under vemurafenib, followed by combination therapy with dabrafenib and trametinib for metastatic melanoma.
    Giurcaneanu C; Nitipir C; Popa LG; Forsea AM; Popescu I; Bumbacea RS
    Acta Dermatovenerol Croat; 2015; 23(2):114-21. PubMed ID: 26228819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective treatment with Dabrafenib and Trametinib for a BRAF-mutated metastatic dedifferentiated malignant spindle cell neoplasm.
    Escandell I; Cabezas M; Martín JM; Terradez L; Pinazo MI
    J Eur Acad Dermatol Venereol; 2016 Jul; 30(7):1224-6. PubMed ID: 25917403
    [No Abstract]   [Full Text] [Related]  

  • 20. Apparent darkening of scalp hair related to pili multigemini Following dabrafenib and trametinib.
    Avila C; Hoffman K; Milani-Nejad N; Pootrakul L
    Dermatol Online J; 2020 Jan; 26(1):. PubMed ID: 32155032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.